iwCLL 2019 | Predicting resistance in CLL patients

Danielle Brander

Danielle Brander, MD, Duke University School of Medicine, Durham, NC, describes the process by which we aim to predict which patients will develop resistance to chronic lymphocytic leukemia (CLL) treatment, with particular reference to venetoclax treatment. This interview was recorded at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Share this video